Correll Christoph U, Rubio Jose M, Citrome Leslie, Mychaskiw Marko A, Thompson Stephen, Franzenburg Kelli R, Suett Mark, Kotak Sameer, Kane John M
Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Neuropsychiatr Dis Treat. 2024 Oct 19;20:1995-2010. doi: 10.2147/NDT.S477674. eCollection 2024.
Despite evidence of benefits beyond those of oral antipsychotics, long-acting injectable antipsychotics (LAIs) are underused in schizophrenia treatment. Underuse may be partially a result of misconceptions held by some healthcare professionals (HCPs) pertaining to LAIs. A panel of four experts convened between January 2022 and May 2022 to identify these misconceptions, and example cases or scenarios were created to illustrate common clinical situations relevant to these beliefs. Ultimately, an online platform and heuristic tool, Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement (S.C.O.P.E.™), was developed to help prescribing clinicians and other HCPs better understand common clinical dilemmas, as well as the place for LAIs in schizophrenia treatment. Three main misconceptions related to the use of LAIs to treat schizophrenia were identified and included "physicians/providers know when patients are nonadherent", "patients do not accept/want LAI treatment", and "LAIs are only appropriate for patients who have demonstrated nonadherence". All misconceptions are refuted by current evidence and were used to develop clinical scenarios with questions to consider when patients present to various sites of care for treatment. These cases are presented on the S.C.O.P.E. educational platform. The platform also includes videos designed to help non-prescribing HCPs and mental health professionals address patient/caregiver concerns and to communicate LAI benefits. In addition, S.C.O.P.E. provides a section with information about each LAI that is currently FDA approved in the United States for the treatment of schizophrenia, to help familiarize HCPs with characteristics of LAIs. S.C.O.P.E. is an educational tool designed for HCPs to help improve their understanding of how to manage common clinical dilemmas in the treatment of people with schizophrenia, to clarify the role of LAIs in medication management, and to increase understanding of the characteristics of available LAIs. S.C.O.P.E. also aims to improve care in schizophrenia by facilitating increased awareness to patients and caregivers.
尽管长效注射用抗精神病药物（LAIs）已被证明具有超出口服抗精神病药物的益处，但在精神分裂症治疗中其使用不足。使用不足可能部分是由于一些医疗保健专业人员（HCPs）对LAIs存在误解。2022年1月至2022年5月期间召集了一个由四位专家组成的小组来识别这些误解，并创建了示例病例或场景以说明与这些观念相关的常见临床情况。最终，开发了一个在线平台和启发式工具，即精神分裂症临床结果场景与医患互动（S.C.O.P.E.™），以帮助开处方的临床医生和其他HCPs更好地理解常见的临床困境，以及LAIs在精神分裂症治疗中的地位。确定了与使用LAIs治疗精神分裂症相关的三个主要误解，包括“医生/医疗服务提供者知道患者何时不依从”、“患者不接受/不想接受LAIs治疗”以及“LAIs仅适用于已表现出不依从的患者”。所有这些误解都被当前证据所驳斥，并被用于开发临床场景以及患者前往不同医疗机构接受治疗时需要考虑的问题。这些病例展示在S.C.O.P.E.教育平台上。该平台还包括一些视频，旨在帮助非开处方的HCPs和心理健康专业人员解决患者/护理人员的担忧，并传达LAIs的益处。此外，S.C.O.P.E.提供了一个部分，其中包含目前美国食品药品监督管理局（FDA）批准用于治疗精神分裂症的每种LAIs的信息，以帮助HCPs熟悉LAIs的特性。S.C.O.P.E.是一种为HCPs设计的教育工具，旨在帮助他们更好地理解如何处理精神分裂症患者治疗中的常见临床困境，阐明LAIs在药物管理中的作用，并增进对现有LAIs特性的了解。S.C.O.P.E.还旨在通过提高患者和护理人员的认识来改善精神分裂症的治疗。
